1665-1146

1665-1146

S1665-11462020000300100

10.24875/bmhim.19000166

Mexico

Mexico

Mexico

Mexico

Mexico

Mexico

Mexico

Mexico

Mexico

00 06 2020

00 06 2020

77 3 100 111

1

2013 368

551-60

2

2015 385

430-40

3

2019 17

233-45

4

1986 140

543-6

5

2003 52

579-83

6

2015 212

1711-8

7

2018 12

326-30

8

2001 344

1917-28

9

2017 390

946-58

10

2019 13

36-43

11

2015 372

835-45

12

2017 62

32-8

13

2016 35

1199-203

14

2013 141

816-26

15

2018 53

605-12

16

2013 132

341-8

17

1996 17

163-8

18

2000 137

865-70

19

RISK-21 Study Group

2017 11

157-64

20

2018 142

21

2017 7

1-10

22

2015 43

298-303

23

2017 36

2-8

24

2017 11

48-56

25

1998 102

531-7

26

2003 143

532-40

27

Palivizumab Outcomes Registry Study Group

2003 35

484-9

28

IRIS Study Group

2003 22

823-7

29

Palivizumab Outcomes Registry Group

2008 29

382-7

30

2011 12

580-8

31

2018 S1526-0542

30139-8

32

2018 5

33

2012 54

47-59

34

2017 17

687

35

2017 7

47

36

2014 134

e620-38

37

2017

38

2017 34

51-61

39

2017 181

183-8.e1

40

2019 209

125-9

41

Comitéde Estándares de la SENeo

2015 82

199.e1-2

42

2012 379

2162-72